RecruitingPhase 2NCT05953610
Endotypic Traits and Obstructive Sleep Apnea Surgery
Sponsor
University of California, Los Angeles
Enrollment
150 participants
Start Date
Jan 7, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
Eligibility
Min Age: 21 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Acetazolamide 500 MG QHS and a drug called Eszopiclone 3 mg QHS for people with obstructive sleep apnea. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAcetazolamide 500 MG QHS
Acetazolamide
DRUGEszopiclone 3 mg QHS
Eszopiclone
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05953610
Related Trials
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT0744437227 locations
Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study
NCT048144203 locations
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT0722676554 locations
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT0722568660 locations
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
NCT041799811 location